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Summary 
This report describes the World Health Organization (WHO) project to develop an international 
standard (IS) for Chikungunya virus (CHIKV) RNA for use with nucleic acid amplification 
technique (NAT)-based assays. An international collaborative study was conducted to determine the 
potency of the candidate standard using a range of NAT-based assays for CHIKV, and to evaluate 
the suitability of the candidate for the calibration of secondary reference materials and the 
standardization of CHIKV viral load measurements. 
The candidate standard consisted of a heat inactivated CHIKV strain of the East/South/Central 
African genotype (ESCA), also known as the Indian Ocean Lineage, isolated from a patient 
returning from India to the United States in 2006
1
, diluted in human negative plasma. The 
lyophilized candidate preparation (Sample 1), the corresponding liquid-frozen bulk material (Sample 
2) and three different clinical samples (Sample 3, Sample 4 and Sample 5) were included in the 
collaborative study. Twenty-five laboratories representing 14 countries participated in the study to 
evaluate the material using their routine CHIKV NAT assays. Twenty-four laboratories returned 31 
data sets from 17 commercial assays and 14 in-house methods. Of these 31 methods, 11 were 
quantitative and 20 were qualitative. 
The results of the study indicate the suitability of the candidate material of the CHIKV strain of 
ESCA genotype (Sample 1) as the proposed 1
st
 WHO IS for CHIKV. It is therefore proposed that 
the candidate material (PEI code 11785/16) is established as the 1
st
 WHO IS for CHIKV RNA for 
NAT-based assays with an assigned potency of 2,500,000 International Units (IU)/mL when 
reconstituted in 0.5 mL of nuclease-free water. 
On-going studies for real-time and accelerated stability of the proposed IS indicate that the 
preparation is stable and suitable for long-term use under the proposed storage conditions. 
 
Introduction 
Chikungunya virus (CHIKV) is an enveloped, positive-sense single stranded RNA alphavirus in the 
family Togaviridae that causes a fever-rash-arthralgia syndrome in humans, known as chikungunya 
fever. The virus is most commonly transmitted in the urban cycle by the mosquitoes Aedes aegypti 
and Aedes albopictus, the same vectors that transmit dengue and Zika virus.
2
 
CHIKV was first recognized in epidemic form in East Africa (Tanzania) in 1952–1953.3, 4 
Following the discovery of CHIKV, numerous subsequent outbreaks have been documented both in 
Africa and Asia. Since 2000, the incidence of large outbreaks has increased with spread of the virus 
to previously non-endemic regions. The current epidemic, ongoing since 2004, involves many 
tropical and sub-tropical areas of Africa, Asia, Europe, the Indian Ocean, the Caribbean and the 
Americas. Autochthonous transmissions have been reported in the Caribbean, the Americas and 
Europe.
5
 In the years 2016 and 2017 current outbreaks have been reported in India and Pakistan.
6
 
Just recently, in August/September 2017, French and Italian authorities reported numerous clustered 
cases of autochthonous CHIKV infection in France and Italy.
7, 8 
 
Genetic analysis of strains have identified three geographically distinct CHIKV lineages: the West 
African lineage, the East/Central/South African (ECSA) lineage, and the Asian lineage derived from 
the ECSA virus.
9
 
About 15% of individuals infected with CHIKV are asymptomatic, but most infections cause a 
febrile illness characterized by high fever and severe joint pain. Other symptoms include muscle 
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pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can last months to years, 
but death from CHIKV infection appears to be extremely rare.
10
 
Owing to the lack of licensed vaccines and antiviral therapeutics, the primary response to CHIKV 
outbreaks is vector-control. However, A. aegypti and A. albopictus populations continue to expand 
in some regions due to the rapid development of insecticide resistance, the lack of education and 
poor infrastructure.
11
 
CHIKV, like other arboviruses, has the potential to be transmitted by transfusion of blood and blood 
products. Measures to prevent possible CHIKV transfusion transmission include deferral of 
symptomatic donors, discontinuing blood collections in affected areas, and CHIKV nucleic acid 
amplification technique (NAT) screening of donations.
12
 
NAT-based assays are considered the most sensitive detection method for laboratory diagnosis and 
blood screening of acute CHIKV infections. Currently, there is no standardization of NAT-based 
assays for the detection of CHIKV RNA. 
The proposal for the establishment of an International Standard (IS) for CHIKV RNA for NAT-
based assays was endorsed by the Expert Committee on Biological Standardization (ECBS) of the 
World Health Organization (WHO) in 2010. The Paul-Ehrlich-Institut (PEI), a WHO Collaborating 
Centre for Quality Assurance of Blood Products and in vitro Diagnostic Devices, has developed a 
candidate IS for CHIKV RNA in collaboration with the Centre for Biologics Evaluation and 
Research (CBER) of the U.S. Food and Drug Administration (FDA). The International Standard was 
prepared in accordance with published WHO recommendations.
13
 
 
Study materials 
Candidate International Standard (11785/16) 
For the preparation of the candidate IS a CHIKV isolate imported in 2006 from India to the United 
States
1
 was selected. The CHIKV strain R91064 was kindly provided by Maria Rios from 
CBER/FDA. The virus has been propagated in cell culture (Vero cells), inactivated by heat-
treatment and characterized within the context of a collaborative study at CBER/FDA as described 
previously by Añez et al..
14
 The complete coding region and partial non-coding region sequences of 
the CHIKV strain R91064 have been determined and made available under the GenBank accession 
number KJ941050.
15
  
For the preparation of the candidate WHO standard bulk, 35 mL of the CHIKV strain R91064 were 
mixed with 1965 mL of human plasma (~1:57 dilution). The bulk preparation was cooled (4-8°C) 
until processing (~18 hours later). The preparation was diluted using pooled citrated human plasma 
which was centrifuged and filtered before use. The plasma diluent tested negative for anti-CHIKV 
IgG and IgM, CHIKV RNA, dengue virus (DENV) RNA, Zika virus (ZIKV) RNA, human 
immunodeficiency virus type 1/2 (HIV-1/2) RNA, hepatitis A virus (HAV) RNA, hepatitis B virus 
(HBV) DNA, hepatitis C virus (HCV) RNA, hepatitis E virus (HEV) RNA and Parvo B19 virus 
DNA. Testing was performed at PEI by using CE marked and in-house validated test methods. In 
addition, the plasma was negative for hepatitis B surface antigen (HBsAg), anti-HCV and anti-HIV-
1/2. 
The filling and lyophilisation was performed by an EN ISO 9001- and EN ISO 13485-certified 
company in Switzerland. Processing took place between the 8
th
 and 11
th
 November 2016. For 
processing, 0.5 mL volumes were dispensed into 4 mL screw-cap glass vials. After completion of 
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the freeze-drying procedure using a CHRIST Epsilon 2-25 D freeze drier (Martin Christ 
Gefriertrocknungsanlagen GmbH, Osterode, Germany), the vacuum was broken by the introduction 
of nitrogen gas and the vials sealed with rubber seals. The vials were further secured with screw 
caps prior to storage at -20°C. 
For the candidate WHO standard, 3524 vials were lyophilized. The mean fill weight was 508.09 mg 
and the coefficient of variation (% CV) of the fill volume was 0.58% with a standard deviation (SD) 
of ± 2.937 mg (n=24). Residual moisture was determined by Karl Fischer analysis and was 0.525% 
(n=12). The freeze-drying process did not significantly affect the CHIKV RNA titre of the 
lyophilized samples when compared to aliquots of the respective bulk preparations which were 
stored at -80°C (data not shown). 
Because the candidate IS was to be assigned a unitage with respect to the CHIKV RNA content, 
homogeneity of the filling/freeze-drying was assessed using real-time PCR. Extraction of RNA was 
performed using 500 µL of the sample using the QIAamp DSP Virus Kit (Qiagen GmbH, Hilden, 
Germany). Elution of viral nucleic acid was performed using 60 µL of elution buffer, and 10 µL of 
the eluate was used for the RT-PCR. Amplification reactions and detection were performed using 
the RealStar
®
 Chikungunya RT-PCR Kit 2.0 (altona Diagnostics, Hamburg, Germany) on the 
LightCycler 480 II instrument (Roche Molecular Diagnostics, Mannheim, Germany) in accordance 
with the manufacturer’s instructions. A standard curve was prepared using an in vitro CHIKV RNA 
transcript kindly provided by altona Diagnostics, Hamburg, Germany. The crossing point-PCR-
cycle or cycle threshold (CT) values were determined for 12 vials of the candidate IS. For each vial 
1:10 and 1:100 dilutions were tested. The mean CT values were 24.94 (1:10) and 28.17 (1:100), 
respectively, with a CV of 0.44% (1:10) and 0.32% (1:100), indicating that the filling was of 
acceptable homogeneity. 
For the international collaborative study both, the lyophilized candidate standard 11785/16 (coded as 
“Sample 1”) and the liquid/frozen bulk material (coded as “Sample 2”) were provided to the 
participants for parallel testing. 
Vials of the candidate WHO IS are held at the Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 
63225 Langen, Germany. The vials are kept at -20°C with continuous temperature monitoring. 
All manufacturing records are held by PEI and are available on request by the WHO Expert 
Committee on Biological Standardization. 
 
Clinical materials 
Sample 3 
This viraemic plasma sample originated from an ill traveller returning to Europe from the Indian 
Ocean region (Mauritius) and was kindly provided by Bernd Kupfer (University of Bonn, Institute 
of Virology, Germany). Plasma has been stored as liquid/frozen material at ≤ -70°C after ~1:500 
dilution in pooled negative human plasma which tested negative for different viral nucleic acids 
including CHIKV RNA at the PEI (see preparation of candidate IS). 
 
Sample 4 
This viraemic plasma came from a Brazilian patient infected with CHIKV and was kindly provided 
by Lia Laura Lewis Ximenez de Souza Rodrigues (Instituto Oswaldo Cruz/Fiocruz, Brazil). Plasma 
has been stored as liquid/frozen material at ≤ -70°C after ~1:200 dilution in pooled negative human 
plasma (see preparation of candidate IS).  
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Sample 5 
This viraemic plasma came from a Brazilian patient infected with CHIKV and was kindly provided 
by Patrícia Alvarez Baptista (Bio-Manguinhos/Fiocruz, Brazil). Plasma has been stored as 
liquid/frozen material at ≤ -70°C after ~1:100 dilution in pooled negative human plasma (see 
preparation of candidate IS). 
 
Collaborative Study 
A total of 34 laboratories from 19 countries located in 4 continents were invited to participate in the 
study. The potential participants were selected because of their recognized expertise in the CHIKV 
diagnostics field and geographic distribution. They represented IVD manufacturers, regulatory 
authorities, as well as clinical, reference and research laboratories. Twenty-five laboratories from 14 
different countries (Americas: 7, Asia: 4, Europe: 13, Australia: 1) agreed to participate in the study 
and received the study samples. One laboratory was unable to return data. The collaborative 
participants are listed in Appendix 1. For the purposes of data analysis, each laboratory has been 
referred to by a code number allocated at random and not representing the order of listing in 
Appendix 1. Qualitative and quantitative results from the same laboratory were identified in the 
figures with the same laboratory code and a letter “A” and “B” to differentiate between qualitative 
and quantitative results, respectively. 
All collaborative study materials were shipped to participating laboratories on dry ice and 
participants were requested to store the materials at or below -20°C (Sample 1) and at or 
below -70°C (Samples 2 to 5) until use. Samples represented a mixture of inactivated reference 
materials as well as a small number of infectious clinical samples. Participants received samples 
representing the ESCA CHIKV lineage (Samples 1 and 2) and unknown CHIKV lineages (Samples 
3 to 5; sequencing analysis is ongoing).  
The samples included in the panel (Samples 1 to 5) are described above. Sufficient materials were 
provided for four separate assay runs. Additional vials were provided for laboratories using larger 
extraction volumes. Laboratory 18 only received the inactivated Samples 1 and 2. 
Participants were asked to test the panel using their routine assay for CHIKV RNA, testing the panel 
of samples in four separate assay runs, using fresh vials of each sample for each run. 
Where laboratories performed quantitative assays, participants were requested to test Sample 1, 
Sample 2, Sample 3, Sample 4 and Sample 5 in the linear range of the test by a series of three one 
log10 dilution steps in all four assay runs. Suggested dilutions to test for each sample were proposed 
in the study protocol (Appendix 3). Results should be reported in copies/mL. 
In the case of qualitative assays, participants were requested to assay Sample 1, Sample 2 and 
Sample 3 by a series of seven one log10 dilution steps to obtain an initial estimate of an end-point. 
For the three subsequent assays, they were requested to assay half-log10 dilutions around the end-
point determined in their first assay. If, in the second assay, all dilutions were positive, or all 
negative, then the dilution series were to be adjusted accordingly for the final assay run. The 
participating laboratories were asked to test Sample 4 and Sample 5 at three one log10 dilution steps 
in all four assay runs. Results were reported as either positive i.e. CHIKV RNA detected or 
negative. 
Participants were asked to note if replicate extractions and replicate amplification/detection steps 
were performed. Electronic data sheets and a method reporting form were provided so that all 
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relevant information (e.g. CT values for the respective dilutions where real-time PCR methods were 
used) could be reported. 
For the preparation of dilutions, participants were requested to use their usual diluent representing 
the matrix of the normal test specimens e.g. CHIKV negative plasma. It was recommended to dilute 
the samples in plasma, or other types of sample matrix that might be used for CHIKV diagnostic 
testing. 
The lyophilized preparation evaluated in the study was reconstituted before use by participants using 
0.5 mL molecular grade, nuclease-free water. After addition of water, it was recommended that the 
samples be left for a minimum of 20 minutes with occasional agitation before use. All other samples 
were provided as liquid/frozen materials. 
 
Statistical Methods 
Quantitative Assays 
Evaluation of quantitative results includes the complete dilution range used by the participants, as 
with correction of the dilution factor the data show comparable results between dilutions. Estimates 
(expressed in log10 NAT-detectable units/mL) for each laboratory, sample and assay were derived 
by the geometric mean from up to 6 replicates. 
 
Qualitative Assays 
For qualitative data analysis, results from all assays were pooled to give the number of positives out 
of the total number tested at each dilution. If it is assumed that a single ‘detectable unit’ will give a 
positive result, and that the probability of a positive result follows a Poisson distribution, the EC63 
(the dilution at which 63% of the samples are expected to be positive) was chosen as the end-point. 
For each laboratory and sample, these end-points were estimated by means of a probit analysis. For 
assays where the change from complete negative to complete positive results occurred in two or 
fewer dilution steps for all samples, the Spearman-Kaerber method was applied for EC63 
estimation. The calculated end-point was used to give estimates expressed in log10 NAT-detectable 
units/mL after correcting for the equivalent volume of the test sample. 
According to the study protocol for qualitative assays, participants were requested to test dilutions of 
Sample 1, Sample 2 and Sample 3 around the end-point determined in the first assay run. In 
contrast, Sample 4 and Sample 5 were to be tested in three ten-fold dilutions (without end-point 
dilution analysis). However, evaluable data for Sample 4 and Sample 5 were included in the analysis 
whenever the end-point was detectable. 
 
Combination of quantitative and qualitative data 
A mean estimate for quantitative data for each sample and laboratory was estimated by means of 
mixed linear model (random factor assay run). These mean estimates were then combined with the 
qualitative data for each sample and laboratory. Distribution of participants, assay types, and diluent 
matrices were graphically presented in histogram form. 
For the candidate reference potency, data from 30 assays were combined. Data from 23 out of 24 
laboratories was included with 7 participants providing data for more than one assay. Most assays 
were qualitative (20 assays, 10 quantitative assays). One assay had to be excluded due to different 
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assay units (plaque-forming units (pfu)/mL) reported, which could not be converted to copies or 
genome equivalents/mL. 
 
Relative potencies 
Potencies of all samples, for the quantitative assays, were estimated relative to the candidate IS 
11785/16 using parallel line analysis of log transformed data. In the case of the qualitative assays, 
the relative potencies were determined using parallel line analysis of probit transformed data. 
For assays reporting CT values, these were evaluated for both qualitative and quantitative methods 
(relative to the reference candidate IS 11785/16 potency) using a parallel line model for each 
laboratory combined for all evaluable (i.e. valid) assay runs. Relative potencies from CT values were 
shown in histogram form to allow for a comparison of participants and assay types. 
Parallel line model and probit analysis were performed according to methods described in chapter 
5.3, “Statistical analysis of results of biological assays and tests”, of the Ph. Eur..16 The statistical 
analysis was performed with SAS
®
/STAT software, version 9.4
17
, and CombiStats software, version 
5.0.
18 
 
Inter- and intra-laboratory variation 
For CT values (relative potencies of both qualitative and quantitative data), variation between 
laboratories (inter-laboratory) as well as variation within laboratories and between assays (intra-
laboratory) was estimated as geometric variation coefficients (%GCV) based on a mixed linear 
model including all individual estimates (random factors labcode and assay type(labcode)). For 
quantitative data, the variability (as combination of inter- and intra-laboratory variation) was 
estimated with a mixed linear model including all individual estimates (with random factors labcode 
and assay run), whereas for qualitative data the variation was estimated simply by means of the ratio 
of the mean estimate divided by the standard deviation (due to only one estimate per laboratory 
available). 
 
Stability Studies 
Stability of the candidate IS is under continuous assessment, through both real-time and accelerated 
thermal degradation stability studies. Vials of the candidate WHO standard have been stored 
at -20°C (the recommended storage temperature) and at -80°C (to provide a baseline if there is any 
suggestion of instability at higher temperatures). For the accelerated thermal degradation, vials have 
been incubated at +4°C, +20°C and +37°C for up to 6 months. After incubation at the respective 
temperatures, the contents of the vials were reconstituted in 0.5 mL of nuclease free water and 
analysed by real-time PCR as described above. Aliquots of the corresponding frozen liquid bulk 
materials storage at -80°C were analysed in parallel. 
 
Results 
Data received 
Data were received from a total of 24 of the 25 participating laboratories. In total, 31 sets of data 
were returned; 11 from quantitative assays and 20 from qualitative assays. Some laboratories 
reported results for more than one type of assay. For the purposes of data analysis, each laboratory 
has been referred to by a code number allocated at random and not representing the order of listing 
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in Appendix 1. Where a laboratory performed more than one assay method, the results from the 
different methods were analysed independently, as if from separate laboratories, and coded, for 
example, laboratory 3A and laboratory 3B. 
For quantitative data, participants returned values as copies/mL or genome equivalents/mL which 
were assumed to be equivalent to copies/mL. Qualitative data was expressed as reactive or non-
reactive. Participants who performed real-time RT-PCR methods reported CT values in addition 
(qualitative and quantitative assays). 
The types of methods used by the participants are listed in Table 1. Assays included in the study 
targeted several different regions of the non-structural and structural protein genes of the CHIKV 
genome. Participants used in-house developed assays based on scientific publications as well as 
commercial assays (including assays under development). The vast majority of assays were based 
on real-time RT-PCR. A range of manual and automated extraction methods as well as different 
types of matrix for dilution of the study samples were used (Table 1). 
Exceptions were as follows: 
Laboratory 9 reported quantitative results as plaque-forming units (pfu)/mL without further 
adjustment on the number of copies or genome equivalents quantifiable by NAT per pfu. Due to 
non-comparability this data set had to be omitted from the evaluation. 
Laboratory 18 did not receive the infectious study material Sample 3, Sample 4 and Sample 5 for 
testing. 
 
Quantitative Assay Results – Mean Estimates 
A total of 11 (35%) data sets for quantitative assays were provided by the participating laboratories. 
Quantitative assays for each study sample were performed over a range of three ten-fold dilutions 
expected to fall in the linear range of the majority of assays. Participants returned values as 
copies/mL or genome equivalents/mL (accounted for dilution). The individual laboratory means are 
given in Table 2. Mean estimates are also shown in histograms in Figures 1-5. Each box represents 
the mean estimate from an individual laboratory and is labelled with the laboratory code number. 
The mean estimates for each study sample in each laboratory were expressed in log10 NAT-
detectable units/mL. Relative variation of the individual laboratory estimates for quantitative assays 
was evaluated with regard to the intra-laboratory standard deviation of log10 NAT-detectable 
units/mL and %GCV (Table 8). 
 
Qualitative Assay Results – Mean Estimates 
A total of 20 (65%) data sets for qualitative assays were provided by the participating laboratories. 
The individual laboratory means are given in Table 3. The NAT-detectable units/mL (log10) for the 
qualitative assays is shown in histograms in Figures 1-5. Each box represents the mean estimate 
from an individual laboratory and is labelled with the laboratory code number. Mean qualitative 
results were considerably lower than quantitative results. From Figures 1-5, it can be seen that the 
qualitative assays are more variable than the quantitative assays, reflecting the different sensitivities 
of the various assays. This observation is not unexpected and is in line with other studies in this 
field. 
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Determination of Overall Laboratory Means – Combined Qualitative and 
Quantitative Results 
The overall mean values and the precision of estimates between laboratories (95% confidence 
interval) for the candidate IS and the other study samples for the qualitative and quantitative assays 
are shown in Table 4. The combined overall mean values for both the qualitative and quantitative 
tests are shown in Table 5 together with the standard deviations and the range of estimates. 
Qualitative assays gave consistently lower mean estimates for all study samples than for the 
quantitative assays, probably as a result of lower sensitivity of qualitative assays. When comparing 
results from Sample 1 and Sample 2 a slight potency loss of 0.27 and 0.37 log10 NAT-detectable 
units/mL for the candidate IS was observed for the mean estimates of both, quantitative and 
qualitative tests, respectively. In conclusion, the lyophilisation of the candidate IS had no significant 
impact on the CHIKV RNA integrity. 
 
Relative Potencies 
On the basis of the combined data from both qualitative and quantitative assays, the candidate WHO 
IS 11785/16 (Sample 1) was determined to have a potency of 6.39 log10 units/mL (95% CI 6.00 – 
6.79). The potencies of the panel of study samples were calculated relative to Sample 1 – the 
candidate IS, taking the value of Sample 1 as 6.39 log10 units/mL. The relative potencies for 
quantitative and qualitative assays are shown in Table 6 and in histograms in Figures 6-9. Overall 
mean estimates and inter-laboratory variation for potency relative to Sample 1 log10 IU/mL are 
summarized in Table 7 for quantitative and qualitative assays as well as for combined data. For 
Sample 2, the liquid bulk material, as well as for the clinical samples, Sample 3, Sample 4 and 
Sample 5, it can be observed that in each case there is a marked reduction in assay variability when 
data are expressed against the common standard. These data provide some evidence for 
commutability of the candidate standard for evaluation of CHIKV from infected individuals and its 
potential to harmonize CHIKV NAT-based assays. Please recognize the scales differences between 
different figures. 
 
Relative potencies CT values 
For the different laboratories and assays where CT values have been reported, data were evaluated 
for both qualitative and quantitative methods relative to the candidate IS (Sample 1) potency of 6.39 
log10 units/mL. The relative potencies from CT values for quantitative and qualitative assays are 
shown in Table 9 and in histograms in Figures 10-13. Overall potency estimates from CT values for 
quantitative and qualitative assays as well as for combined data are summarized in Table 10. The 
data show that potencies estimated by the alternative statistical method based on CT values are 
comparable to those obtained using the conventional method described above. Please recognize the 
scales differences between different figures. 
Table 11 shows the variability of relative potencies (from up to 4 assays per laboratory) based on CT 
values from qualitative and quantitative assays. As already observed in the figures above (Figures 
10-13), for Sample 4 and Sample 5, the between laboratory variability is distinctly higher than for 
Sample 2 and Sample 3. 
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Evaluation of CT values 
In order to evaluate the commutability of the candidate IS, comparative testing of three clinical 
samples (Sample 3, Sample 4 and Sample 5) was performed within the international collaborative 
study and CT values reported for qualitative and quantitative real-time PCR assays have been 
analysed in this regard. The analysis included 30 data sets, 11 from quantitative and 19 from 
qualitative real-time PCR assays used in the collaborative study. Data demonstrated that the 
candidate IS and the clinical samples were detected with comparable efficiency (data not shown). 
Furthermore, the mean CT values of the liquid bulk material (Sample 2) and the clinical samples 
(Sample 3, Sample 4 and Sample 5) were compared with the corresponding mean CT values of the 
candidate IS (Sample 1). The relationship of mean CT values between the Sample 1 and Sample 2, 
Sample 3, Sample 4 and Sample 5 (based on data of 1:10 dilution) is shown in Figure 15. The 
relative concentration of Sample 2 (liquid-frozen candidate IS material) from most assays is slightly 
higher compared to the relative concentration of Sample 1 (up to 1 CT value), which demonstrated 
that the lyophilisation had no significant effect on the integrity of CHIKV RNA. Only results from 
assays 23A/B provided a CT values difference of about 2. Almost all laboratories included in the 
evaluation detected the clinical samples (Sample 3, Sample 4 and Sample 5) with a lower 
concentration when compared to the candidate IS (as expected). However, for Sample 4 and Sample 
5 the between laboratory variability is distinctly higher than for Sample 3. 
 
Results of Stability Studies 
Vials of the candidate WHO standard were incubated at +4°C, +20°C and +37°C for up to 6 months 
and tested by real-time PCR for CHIKV RNA. The heat-treated vials were assayed concurrently 
with control vials that had been stored at -20°C and at -80°C, in duplicate. Summarized results of 
stability studies are shown in Table 12 and Figure 14, respectively. 
There was no evidence of instability of the samples stored at -20°C when compared to samples 
stored at -80°C. Thus, the results from the testing suggest that the lyophilized preparation is stable 
when stored at the recommended storage temperature at -20°C or below. Real-time stability studies 
have also indicated that the candidate IS is stable after 6 months incubation at +20°C. As there was 
no significant reduction in CHIKV RNA this would support shipment at ambient temperature. The 
most significant loss of titre (~ 1.3 log10) was observed for the candidate material when stored for 6 
months at +37°C. Thus, the lyophilized candidate IS should be protected from extreme temperatures 
when transported. 
The potency of the reconstituted material, after freezing and thawing, has not been investigated. 
Accelerated and real-time stability studies are on-going and will be communicated to the WHO. 
All raw data for the collaborative study and stability analysis are held by PEI and are available on 
request by the ECBS. 
 
Conclusions 
In this collaborative study, various quantitative and qualitative assays were employed to determine 
the potency of the candidate IS for CHIKV RNA and to evaluate its suitability for use in NAT-based 
assays. Collaborators used a wide range of methods, both in-house developed and commercially 
available, for extraction of nucleic acids and for amplification/detection. Approximately half of the 
data sets received were from laboratory-developed assays. The other half of the data sets was 
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received from assays available commercially or under development by kit manufacturers. The 
different samples included in the study were well detected by the participating laboratories, with 
some differences in efficiency of detection of some of the samples. Results of the study provide 
evidence that the lyophilisation of the candidate IS had no great impact on the integrity of the viral 
nucleic acid. 
Real-time stability studies have indicated that the candidate IS is stable under normal conditions of 
storage, i.e. at -20°C or below for 6 months and therefore suitable for long term use as well as at 
elevated temperatures, i.e. after 6 months incubation at +20°C there was no significant reduction in 
CHIKV RNA which would support shipment at ambient temperature. Initial accelerated thermal 
degradation analysis indicates a reduction in the levels of CHIKV RNA at higher incubation 
temperatures (e.g. +37°C). Shipment at extreme temperatures should therefore be avoided. On-going 
studies on the real-time stability under normal storage conditions as well as studies concerning 
thermal degradation are in progress. 
The draft “Instructions for Use” for the candidate IS includes details for storage and reconstitution 
of the material (Appendix 2). Each vial contains the lyophilized residue of 0.5 mL of inactivated 
CHIKV in human plasma to be reconstituted in 0.5 mL of nuclease-free water. Based upon the 
qualitative and quantitative results of the collaborative study, the candidate WHO IS was estimated 
to have a potency of 6.39 log10 units/mL. 
The standard will be of value for comparison of results between laboratories, determination of assay 
sensitivities and for validation. It is anticipated that the standard will find application in clinical, 
reference, and research laboratories as well as blood transfusion services, regulatory authorities and 
manufacturers of in vitro diagnostic kits. 
 
Recommendations 
Based on the results of the international collaborative study, it is proposed that the heat-inactivated, 
lyophilized CHIKV strain (Sample 1 in this study), should be established as the 1
st
 International 
Standard for CHIKV RNA with a unitage of 2,500,000 IU/mL. The standard has been given the 
code number 11785/16. 3200 vials are available to the WHO and the custodian laboratory is the 
Paul-Ehrlich-Institut.
*
 
 
Responses from participants 
After circulation of the draft report for comment, nine out of twenty-five participants responded to 
the report. There were no disagreements with the suitability of the candidate IS (PEI code 11785/16) 
to serve as the 1
st
 WHO International Standard for CHIKV RNA for NAT-based assays. The 
majority of the comments were editorial in nature and the report has been amended accordingly 
where appropriate. 
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Table 1. Assay protocols used by participants. 
Laboratory 
code 
Assay type 
(qualitative / 
quantitative) 
Extraction method NAT method Assay target Quantification 
standard 
Diluent Reference 
1 qualitative Exiprep™16 Dx Viral RNA kit on 
Exiprep™16 Dx (Bioneer Corp.) 
Real-time RT-PCR (AccuPower 
ZIKV, DENV, CHIKV Multiplex 
Real-Time RT-PCR Kit, Bioneer 
Corp.) 
Not stated n/a Plasma  
2 quantitative ZR Viral RNA Kit™ (Zymo 
Research) 
Real-time RT-PCR Structural polyprotein 
gene (E1 envelope) 
Synthetic E1 
region RNA 
Not stated Lim CK et al., 2009 
3A quantitative MagNA Pure LC Total Nucleic 
Acid Isolation Kit on MagNA Pure 
LC instrument (Roche) 
Real-time RT-PCR (TaqMan; 
LightMix Modular Chikungunya virus 
duplex PCR, TIB Molbiol) 
Structural polyprotein 
gene (envelope) 
in vitro 
transcribed 
RNA 
Human plasma  
3B quantitative MagNA Pure LC Total Nucleic 
Acid Isolation Kit on MagNA Pure 
LC instrument (Roche) 
Real-time RT-PCR (TaqMan; 
LightMix Modular Chikungunya virus 
in multiplex PCR (CHIKV, DENV, 
ZIKAV, ECT), TIB Molbiol) 
Structural polyprotein 
gene (envelope) 
in vitro 
transcribed 
RNA 
Human plasma  
4 qualitative Sentosa SX Virus Total Nucleic 
Acid Kit v2.0 on Sentosa SX101 
(Vela Research Singapore Pte Ltd) 
Real-time RT-PCR  Structural polyprotein 
gene (E1 envelope) 
n/a EDTA plasma  
5 qualitative Magnetic based sample processing 
on Panther System (Grifols Inc.) 
Real-time transcription mediated 
amplification 
Structural polyprotein 
gene 
n/a Not stated  
6A qualitative NucliSENS® easy MAG 
(bioMérieux) 
Real-time RT-PCR (TaqMan; FTD-36 
Tropical fever core assay) 
Structural polyprotein 
gene (E1 envelope) 
n/a Plasma  
6B qualitative NucliSENS® easy MAG 
(bioMérieux) 
Real-time RT-PCR (TaqMan; FTD-43 
Dengue/Chik assay) 
Structural polyprotein 
gene (E1 envelope) 
n/a Plasma  
7 qualitative cobas® 6800/8800 (Roche) Real-time RT-PCR (cobas® 
CHIKV/DENV (in development), 
Roche) 
Not stated n/a Human plasma  
8 quantitative QIAamp Viral RNA Mini Kit 
(Qiagen) 
Real-time RT-PCR (RealStar® 
Chikungunya RT-PCR Kit 2.0, altona 
Diagnostics) 
Not stated in vitro 
transcribed 
RNA 
EDTA plasma  
9 quantitative QIAamp Viral RNA Mini Kit 
(Qiagen) 
Real-time RT-PCR Non-structural poly-
protein gene (nsP1) 
RNA from viral 
stocks 
DMEM  
10 quantitative QIAamp Viral RNA Mini Kit 
(Qiagen) 
Real-time RT-PCR (RealStar® 
Chikungunya RT-PCR Kit 2.0, altona 
Diagnostics) 
Not stated in vitro 
transcribed 
RNA 
Human serum  
11 qualitative MagCore® Viral Nucleic Acid 
Extraction Kit on MagCore® 
Automatic Nucleic Acid Extractor 
(RBC Bioscience) 
Real-time RT-PCR Nonstructural poly-
protein gene (nsP1) 
n/a Nuclease-free 
water 
 
12 qualitative QIAamp MinElute Virus Spin Kit 
(Qiagen) 
Real-time RT-PCR (TaqMan) Structural polyprotein 
gene (E1 envelope) 
n/a Supplied with 
the extraction 
kit 
Pongsiri P et al., 2012 
13 qualitative Exiprep™16 Dx Viral RNA kit on 
Exiprep™16 Dx (Bioneer Corp.) 
Real-time RT-PCR (AccuPower 
ZIKV, DENV, CHIKV Multiplex 
Real-Time RT-PCR Kit, Bioneer 
Corp.) 
Non-structural poly-
protein gene 
n/a Human plasma  
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14A qualitative NucliSENS® easy MAG 
(bioMérieux) 
Real-time RT-PCR (TaqMan) Non-structural poly-
protein gene (nsP1) 
n/a Basematrix 
(Seracare) 
Lanciotti RS et al., 2007 
(modified) 
14B quantitative NucliSENS® easy MAG 
(bioMérieux) 
Real-time RT-PCR (TaqMan) Non-structural poly-
protein gene (nsP1) 
in vitro 
transcribed 
RNA 
Basematrix 
(Seracare) 
Lanciotti RS et al., 2007 
(modified) 
15 qualitative Silica columns on BioRobot® MDx 
instrument (Qiagen) 
Real-time RT-PCR (TaqMan; Kit 
Molecular ZDC Bio-Manghuinhos) 
Non-structural poly-
protein gene (nsP1) 
n/a Elution buffer  
16A qualitative NucliSENS® easy MAG 
(bioMérieux) 
Real-time RT-PCR (TaqMan) Non-structural poly-
protein gene (nsP2) 
n/a Not stated Lanciotti RS et al., 2007 
16B qualitative NucliSENS® easy MAG 
(bioMérieux) 
Real-time RT-PCR (TaqMan) Structural polyprotein 
gene (envelope) 
n/a Not stated Pongsiri P et al., 2012 
17 qualitative MagNA Pure LC Total Nucleic 
Acid Isolation Kit on MagNA Pure 
LC instrument (Roche) 
Real-time RT-PCR (TaqMan) Non-structural poly-
protein gene (nsP1) 
n/a Not stated Panning M et al., 2008 
18 qualitative QIAamp Viral RNA Mini Kit 
(Qiagen) 
Real-time RT-PCR (Chikungunya 
Virus Real Time RT-PCR Kit, 
Liferiver) 
Not stated n/a Human plasma  
19A qualitative QIAamp Viral RNA Mini Kit on 
QIACube instrument (Qiagen) 
Real-time RT-PCR (RealStar® 
Chikungunya RT-PCR Kit 2.0, altona 
Diagnostics) 
Not stated in vitro 
transcribed 
RNA 
Foetal bovine 
serum 
 
19B quantitative QIAamp Viral RNA Mini Kit on 
QIACube instrument (Qiagen) 
Real-time RT-PCR Non-structural poly-
protein gene (nsP1) 
n/a Foetal bovine 
serum 
Panning M et al., 2008 
20 qualitative QIAamp Viral RNA Mini Kit on 
QIACube instrument (Qiagen) 
Real-time RT-PCR (RealStar® 
Chikungunya RT-PCR Kit, altona 
Diagnostics) 
Not stated n/a Fresh-frozen 
plasma 
 
21 quantitative DNA and Viral NA Small Volume 
Kit on MagNA Pure 96 instrument 
(Roche) 
Real-time RT-PCR Non-structural poly-
protein gene (nsP1) 
in vitro 
transcribed 
RNA 
Molecular 
Biology Water 
Panning M et al., 2008 
22 qualitative QIAamp Viral RNA Mini Kit 
(Qiagen) 
Real-time RT-PCR Non-structural poly-
protein gene 
n/a Nuclease-free 
water 
Powers AM et al., 2010 
23A qualitative QIAamp Viral RNA Mini Kit on 
QIACube instrument (Qiagen) 
Real-time RT-PCR (TaqMan) Structural polyprotein 
gene (E1 envelope) 
n/a Basematrix Edwards CJ et al., 2007 
23B quantitative QIAamp Viral RNA Mini Kit on 
QIACube instrument (Qiagen) 
Real-time RT-PCR (TaqMan) Structural polyprotein 
gene (E1 envelope) 
CHIKV positive 
tissue culture 
supernatant 
Basematrix Edwards CJ et al., 2007 
24A qualitative QIAamp DSP Virus Kit (Qiagen) Real-time RT-PCR (RealStar® 
Chikungunya RT-PCR Kit 2.0, altona 
Diagnostics) 
Not stated n/a Human plasma  
24B quantitative QIAamp DSP Virus Kit (Qiagen) Real-time RT-PCR (RealStar® 
Chikungunya RT-PCR Kit 2.0, altona 
Diagnostics) 
Not stated in vitro 
transcribed 
RNA 
Human plasma  
n/a = not applicable
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Table 2. Laboratories mean estimates from quantitative assays (log10 NAT-detectable units/mL). 
 
Laboratory code 
Sample 1 Sample 2 Sample 3 
Mean 95% CI
1)
 Mean 95% CI
1)
 Mean 95% CI
1)
 
2 8.59 8.34 – 8.85 8.86 8.74 – 8.98 8.43 8.11 – 8.76 
3A 7.36 7.04 – 7.68 7.67 7.35 – 7.99 7.09 6.77 – 7.41 
3B 7.56 7.25 – 7.87 7.86 7.74 – 7.98 7.28 6.96 – 7.60 
8 7.33 7.20 – 7.46 7.62 7.50 – 7.74 7.07 6.99 – 7.14 
9 
2) – 2) – 2) – 
10 7.42 7.07 – 7.77 7.85 7.50 – 8.19 7.05 6.66 – 7.44 
14B 6.88 6.69 – 7.07 7.13 6.91 – 7.35 6.71 6.55 – 6.86 
19B 7.67 7.14 – 8.21 7.94 7.44 – 8.44 7.37 6.81 – 7.94 
21 6.89 6.71 – 7.07 7.05 6.90 – 7.19 6.73 6.61 – 6.85 
23B 5.23 4.72 – 5.74 5.51 5.20 – 5.82 5.01 4.76 – 5.26 
24B 7.45 7.40 – 7.51 7.64 7.46 – 7.81 7.27 7.15 – 7.40 
Laboratory code 
Sample 4 Sample 5   
Mean 95% CI
1)
 Mean 95% CI
1)
 
2 6.94 6.80 – 7.08 6.91 6.68 – 7.13 
3A 6.11 5.75 – 6.46 6.00 5.59 – 6.41 
3B 6.45 6.19 – 6.71 6.43 5.97 – 6.88 
8 5.70 5.59 – 5.81 5.69 5.54 – 5.84 
9 
2) – 2) – 
10 5.77 5.32 – 6.22 5.94 5.58 – 6.31 
14B 4.95 4.89 – 5.02 5.00 4.93 – 5.07 
19B 6.06 5.50 – 6.62 6.10 5.55 – 6.66 
21 6.04 5.78 – 6.30 6.02 5.85 – 6.18 
23B 3.62 3.11 – 4.14 3.80 3.26 – 4.34 
24B 6.28 6.08 – 6.49 6.28 6.07 – 6.49 
1)
 95% confidence interval 
2)
 Data were omitted from the evaluation due to non-comparable units (pfu/mL) reported 
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Table 3. Laboratories mean estimates from qualitative assays (log10 NAT-detectable units/mL). 
 
Laboratory code 
Sample 1 Sample 2 Sample 3 
Mean 95% CI
1)
 Mean 95% CI
1)
 Mean 95% CI
1)
 
1 5.12 4.88 – 5.31 5.27 5.04 – 5.46 4.90 4.65 – 5.09 
4 4.69 4.54 – 4.83 5.11 4.96 – 5.25 4.99 4.85 – 5.13 
5 6.24 6.09 – 6.38 6.40 6.30 – 6.51 6.40 6.30 – 6.51 
6A 7.56 6.95 – 8.55 8.36 7.49 – 9.78 7.77 7.10 – 8.87 
6B 6.11 5.89 – 6.31 6.29 6.07 – 6.49 6.32 6.10 – 6.52 
7 6.74 6.52 – 6.93 6.93 6.71 – 7.13 6.71 6.49 – 6.90 
11 4.41 4.17 – 4.64 4.66 4.42 – 4.90 4.21 3.92 – 4.51 
12 4.44 4.06 – 4.80 4.87 4.47 – 5.28 4.82 4.45 – 5.17 
13 5.59 5.42 – 5.76 5.72 5.54 – 5.88 5.24 5.07 – 5.40 
14A 6.09 5.87 – 6.31 6.44 6.22 – 6.67 6.07 5.86 – 6.29 
15 6.10 5.69 – 6.55 6.41 5.96 – 6.92 6.34 5.90 – 6.83 
16A 5.87 5.73 – 6.01 6.08 6.00 – 6.15 5.87 5.73 – 6.01 
16B 5.99 5.83 – 6.15 6.19 6.01 – 6.35 5.99 5.83 – 6.15 
17 6.58 6.33 – 6.82 7.28 7.04 – 7.51 6.60 6.36 – 6.83 
18 5.28 5.02 – 5.55 5.62 5.62 – 5.62 2) – 
19A 6.95 6.82 – 7.08 6.87 6.73 – 7.01 3) – 
20 7.12 6.50 – 7.62 7.61 6.99 – 8.11 7.56 6.97 – 8.06 
22 5.47 5.15 – 5.75 6.58 6.27 – 6.86 5.87 5.57 – 6.15 
23A 6.09 5.81 – 6.35 6.58 6.30 – 6.84 6.31 6.03 – 6.57 
24A 7.02 6.66 – 7.34 7.49 7.13 – 7.85 6.86 6.50 – 7.18 
Laboratory code 
Sample 4 Sample 5 
  
Mean 95% CI
1)
 Mean 95% CI
1)
 
1 3.47 3.25 – 3.74 3.40 3.17 – 3.62 
4 3.92 3.27 – 4.56 3.92 3.27 – 4.56 
5 
4) – 4) – 
6A 
4)
 – 4) – 
6B 
4)
 – 4) – 
7 
4)
 – 4) – 
11 3.05 2.74 – 3.35 3.37 3.06 – 3.67 
12 3.91 3.40 – 4.40 3.47 2.97 – 3.93 
13 3.37 3.18 – 3.55 3.27 3.06 – 3.44 
14A 4.07 3.79 – 4.33 4.07 3.79 – 4.33 
15 4.34 3.89 – 4.89 4.94 4.26 – 5.84 
16A 4.97 4.70 – 5.24 4.80 4.52 – 5.09 
16B 4.91 4.73 – 5.08 4.96 4.78 – 5.14 
17 
4)
 – 4) – 
18 
2)
 – 2) – 
19A 
4)
 – 4) – 
20 5.46 4.56 – 6.26 5.46 4.56 – 6.26 
22 4.52 4.12 – 4.93 4.52 4.12 – 4.93 
23A 4.14 3.79 – 4.48 4.15 3.79 – 4.49 
24A 
4)
 – 4) – 
1)
 95% confidence interval 
2)
 Laboratory 18 did not receive Sample 3, Sample 4 and Sample 5 for testing 
3)
 Invalid (curve not parallel) 
4)
 All dilutions positive, no cut-off detectable 
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Table 4. Overall mean estimates and inter-laboratory variation from quantitative and qualitative 
assays (log10 NAT-detectable units/mL). 
 
Sample Assay type N
1)
 Mean
2)
 95% CI
2)
 SD
2)
 %GCV
2) 
Min Max 
1 
quantitative 10 7.24 6.36 – 8.12 0.91 13 5.23 8.59 
qualitative 20 5.97 5.56 – 6.39 0.89 15 4.41 7.56 
2 
quantitative 10 7.51 6.64 – 8.38 0.90 12 5.51 8.86 
qualitative 20 6.34 5.89 – 6.78 0.95 15 4.66 8.36 
3 
quantitative 10 7.00 6.14 – 7.86 0.91 13 5.01 8.43 
qualitative 18 6.05 5.58 – 6.51 0.94 16 4.21 7.77 
4 
quantitative 10 5.79 4.87 – 6.72 0.99 17 3.62 6.94 
qualitative 12
3)
 4.18 3.73 – 4.63 0.71 17 3.05 5.46 
5 
quantitative 10 5.82 4.94 – 6.70 0.95 16 3.80 6.91 
qualitative 12
3)
 4.19 3.72 – 4.66 0.74 18 3.27 5.46 
1)
 Number of data sets 
2)
 Estimates, standard deviation (SD), geometric coefficient of variation (%GCV), and 95% confidence interval (95% 
   CI) based on mixed linear model including random factors participant and assay for quantitative data; for qualitative 
   data based mean of participant’s cut-offs 
3)
 Evaluable data from 10-fold dilution series 
 
 
Table 5. Overall mean estimates and inter-laboratory variation – combined data from quantitative 
and qualitative assays (log10 NAT-detectable units/mL). 
 
Sample N
1)
 Mean
2)
 95% CI
3)
 SD
4)
 %GCV
5) 
Min Median Max 
1 30 6.39 6.00 – 6.79 1.05 16 4.41 6.41 8.59 
2 30 6.73 6.33 – 7.13 1.07 16 4.66 6.73 8.86 
3 28 6.39 6.00 – 6.78 1.01 16 4.21 6.50 8.43 
4 
22 4.91 4.41 – 5.42 1.14 23 3.05 4.93 6.94 
10
6)
 5.79 4.87 – 6.72 0.92 16 3.62 6.05 6.94 
5 
22 4.93 4.43 – 5.43 1.14 23 3.27 4.95 6.91 
10
6)
 5.82 4.94 – 6.70 0.86 15 3.80 6.01 6.91 
1)
 Number of data sets from qualitative and quantitative data 
2)
 Overall mean estimate (log10 NAT-detectable units/mL) based on mean estimates of each data set 
3)
 95% confidence interval 
4)
 Standard deviation 
5) 
Geometric coefficient of variation 
6)
 Excluding data sets from qualitative assays, as not tested according to the end-point dilution protocol 
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Table 6. Laboratory estimates of potency relative to Sample 1 log10 IU/mL from quantitative and 
qualitative assays (taking the candidate WHO IS as 6.39 log10 IU/mL). 
 
Laboratory code Assay type Sample 2 Sample 3 Sample 4 Sample 5 
1 qualitative 6.54 6.17 4.74 4.66 
2 quantitative 6.66 6.23 4.74 4.71 
3A quantitative 6.71 6.13 5.14 5.03 
3B quantitative 6.70 6.11 5.28 5.26 
4 qualitative 6.82 6.70 5.63 5.63 
5 qualitative 6.56 6.56 
1) 1) 
6A qualitative 7.20 6.61 
1) 1) 
6B qualitative 6.57 6.60 
1) 1) 
7 qualitative 6.58 6.36 
1) 1) 
8 quantitative 6.68 6.13 4.77 4.76 
10 quantitative 6.82 6.02 4.75 4.92 
11 qualitative 6.65 6.19 5.04 5.36 
12 qualitative 6.82 6.78 5.86 5.42 
13 qualitative 6.52 6.04 4.17 4.07 
14A qualitative 6.75 6.38 4.37 4.37 
14B quantitative 6.65 6.22 4.47 4.51 
15 qualitative 6.70 6.63 4.64 5.23 
16A qualitative 6.60 6.39 
1)
 
1)
 
16B qualitative 6.59 6.39 5.31 5.36 
17 qualitative 7.10 6.42 
1)
 
1)
 
18 qualitative 6.73 
2)
 
2)
 
2)
 
19A qualitative 6.31 
1)
 
1)
 
1)
 
19B quantitative 6.66 6.10 4.78 4.83 
20 qualitative 6.89 6.83 4.73 4.73 
21 quantitative 6.55 6.23 5.54 5.52 
22 qualitative 7.51 6.79 5.45 5.45 
23A qualitative 6.89 6.61 4.45 4.46 
23B quantitative 6.68 6.18 4.79 4.96 
24A qualitative 6.87 6.24 
1)
 
1)
 
24B quantitative 6.58 6.21 5.22 5.22 
1)
 Data not estimable 
2)
 Laboratory 18 did not receive Sample 3, Sample 4 and Sample 5 for testing. 
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Table 7. Overall mean estimates and inter-laboratory variation for potencies relative to Sample 1 
log10 IU/mL (taking the candidate WHO IS as 6.39 log10 IU/mL) – quantitative and qualitative 
assays as well as combined data. 
 
Sample Assay type N
1)
 Mean
2)
 95% CI
3)
 SD
4)
 %GCV
5) 
Min Max 
2 
quantitative 10 6.67 6.62 – 6.72 0.07 1 6.55 6.82 
qualitative 20 6.76 6.63 – 6.89 0.27 4 6.31 7.51 
combined 30 6.73 6.64 – 6.81 0.23 3 6.31 7.51 
3 
quantitative 10 6.16 6.11 – 6.21 0.07 1 6.02 6.23 
qualitative 18 6.48 6.37 – 6.60 0.23 4 6.04 6.83 
combined 28 6.37 6.27 – 6.46 0.25 4 6.02 6.83 
4 
quantitative 10 4.95 4.71 – 5.19 0.33 7 4.47 5.54 
qualitative 11
6)
 4.95 4.57 – 5.32 0.55 11 4.17 5.86 
combined 21 4.95 4.74 – 5.15 0.45 9 4.17 5.86 
5 
quantitative 10 4.97 4.76 – 5.19 0.30 6 4.51 5.52 
qualitative 11
6)
 4.98 4.62 – 5.33 0.53 11 4.07 5.63 
combined 21 4.97 4.78 – 5.17 0.43 9 4.07 5.63 
1)
 Number of evaluable data sets 
2)
 Mean estimate 
3)
 95% confidence interval 
4)
 Standard deviation 
5) 
Geometric coefficient of variation 
6)
 Evaluable data from 10-fold dilution series 
 
 
Table 8. Intra-laboratory standard deviation of log10 NAT-detectable units/mL and %GCV for 
quantitative assays. 
 
Laboratory code 
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
SD
1)
 %GCV
2) 
SD
1)
 %GCV
2) 
SD
1)
 %GCV
2) 
SD
1)
 %GCV
2) 
SD
1)
 %GCV
2) 
2 0.17 2.0 0.19 2.1 0.19 2.3 0.15 2.2 0.18 2.5 
3A 0.21 2.9 0.20 2.6 0.22 3.1 0.32 5.3 0.42 6.9 
3B 0.24 3.2 0.14 1.8 0.24 3.3 0.31 4.8 0.37 5.8 
8 0.09 1.2 0.09 1.1 0.09 1.3 0.17 2.9 0.26 4.6 
10 0.54 7.3 0.53 6.8 0.42 5.9 0.53 9.1 0.56 9.4 
14B 0.12 1.7 0.13 1.9 0.10 1.5 0.07 1.4 0.05 0.9 
19B 0.36 4.6 0.35 4.4 0.43 5.8 0.42 7.0 0.46 7.5 
21 0.20 2.9 0.16 2.3 0.13 2.0 0.23 3.8 0.16 2.7 
23B 0.42 8.1 0.31 5.6 0.48 9.6 0.55 15.0 0.57 14.9 
24B 0.09 1.2 0.12 1.6 0.13 1.8 0.32 5.1 0.32 5.1 
1)
 Standard deviation 
2) 
Geometric coefficient of variation 
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Table 9. Laboratory estimates of potency relative to Sample 1 log10 IU/mL from quantitative and 
qualitative assays based on CT values (taking the candidate WHO IS as 6.39 log10 IU/mL). 
 
Laboratory code Assay type Sample 2 Sample 3 Sample 4 Sample 5 
1 qualitative 6.59 6.23 4.76 4.61 
2 quantitative 6.67 6.22 4.68 4.62 
3A quantitative 6.74 6.14 5.21 5.22 
3B quantitative 6.73 6.07 5.22 5.17 
4 qualitative 6.76 6.48 5.56 5.45 
5 qualitative 
1)
 
1)
 
1) 1) 
6A qualitative 6.67 6.51 5.60 5.55 
6B qualitative 6.56 6.49 5.57 5.55 
7 qualitative 6.58 6.16 5.24 5.19 
8 quantitative 6.69 6.15 4.76 4.75 
9 quantitative 6.87 6.42 5.74 5.68 
10 quantitative 6.59 5.31 3.62 3.94 
11 qualitative 6.63 6.11 5.98 5.97 
12 qualitative 6.71 6.24 5.24 4.81 
13 qualitative 6.66 6.09 4.11 4.09 
14A qualitative 6.62 6.12 5.53 4.41 
14B quantitative 6.69 6.18 4.59 
2) 
15 qualitative 6.65 6.39 4.92 5.05 
16A qualitative 6.62 6.23 5.37 5.40 
16B qualitative 6.64 6.33 5.19 5.25 
17 qualitative 6.77 6.08 5.26 5.21 
18 qualitative 6.41 
3)
 
3)
 
3)
 
19A qualitative 6.53 7.47 5.26 4.56 
19B quantitative 6.72 5.92 
2)
 4.03 
20 qualitative 7.17 6.14 
2)
 
2)
 
21 quantitative 6.54 6.19 5.46 5.36 
22 qualitative 7.22 6.64 5.40 5.48 
23A qualitative 6.58 6.17 4.63 4.77 
23B quantitative 6.75 5.96 4.83 4.89 
24A qualitative 6.44 6.44 5.16 5.09 
24B quantitative 6.59 6.19 
2)
 
2)
 
1)
 Assay is not based on real-time PCR (no CT values available) 
2)
 Data not estimable 
3)
 Laboratory 18 did not receive Sample 3, Sample 4 and Sample 5 for testing. 
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Table 10. Overall mean estimates for potencies relative to Sample 1 log10 IU/mL based on CT 
values (taking the candidate WHO IS as 6.39 log10 IU/mL) – quantitative and qualitative assays as 
well as combined data. 
 
Sample Assay type N
1)
 Mean
2)
 95% CI
3)
 
2 
quantitative 11 6.69 6.63 – 6.75 
qualitative 19 6.67 6.58 – 6.77 
combined 30 6.68 6.28 – 7.07 
3 
quantitative 11 6.07 5.88 – 6.26 
qualitative 18 6.35 6.19 – 6.51 
combined 29 6.21 4.41 – 8.01 
4 
quantitative 9 4.90 4.43 – 5.37 
qualitative 17 5.16 4.93 – 5.40 
combined 26 5.06 3.43 – 6.69 
5 
quantitative 9 4.85 4.40 – 5.30 
qualitative 17 5.08 4.83 – 5.33 
combined 26 5.00 3.57 – 6.43 
1)
 Number of evaluable data sets 
2)
 Mean estimate 
3)
 95% confidence interval 
 
 
Table 11. Variability of relative potencies based on CT values. 
 
Source of Variation
1)
 Sample 2 Sample 3 Sample 4 Sample 5 
Laboratory
2)
 14% 46% 143% 166% 
Assay Type
3)
 11% 34% 47% 35% 
Residual
4)
 41% 83% 57% 36% 
Total (UM)
5)
 46% 113% 198% 194% 
1)
 Geometric coefficient of variation (GCV) for variability of relative potencies 
2)
 Inter-laboratory variability 
3)
 Inter-assay variability (qualitative/quantitative) 
4)
 Intra-assay variability (between up to 4 assays per lab) 
5)
 Total variability (UM = uncertainty of measurement) 
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Table 12. Stability and accelerated degradation studies after 1, 2 and 3 weeks and after 1, 2, 3 and 6 
months – difference to baseline samples stored at -20°C and -80°C is shown. 
 
Temperature Mean log10 copies/mL* 
1 week 2 weeks 3 weeks 1 month 2 months 3 months 6 months 
-80°C 7.39 7.30 7.32 7.35 7.27 7.42 7.33 
-20°C 7.34 7.30 7.34 7.34 7.30 7.34 7.31 
+4°C 7.32 7.36 7.31 7.30 7.32 7.39 7.33 
+20°C 7.30 7.31 7.25 7.35 7.30 7.32 7.15 
+37°C 7.23 7.20 7.06 7.17 6.80 6.66 5.96 
Temperature Difference in log10 copies/mL from -20°C baseline sample 
+4°C 0.02 -0.06 0.03 0.04 -0.02 -0.05 -0.02 
+20°C 0.04 -0.01 0.09 -0.01 0.00 0.02 0.16 
+37°C 0.11 0.10 0.28 0.17 0.50 0.68 1.35 
Temperature Difference in log10 copies/mL from -80°C baseline sample 
+4°C 0.07 -0.06 0.01 0.05 -0.05 0.03 0.00 
+20°C 0.09 -0.01 0.07 0.00 -0.03 0.10 0.18 
+37°C 0.16 0.10 0.26 0.18 0.47 0.76 1.37 
* RealStar
®
 Chikungunya RT-PCR Kit 2.0, altona Diagnostics 
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Figure 1. Laboratories mean estimates for the candidate WHO standard 11785/16 (Sample 1). 
Estimates of log10 NAT-detectable units/mL are indicated on the x-axis. White squares represent 
quantitative assays and grey squares represent qualitative assays. 
 
 
 
 
 
Figure 2. Laboratories mean estimates for the liquid/frozen bulk material (Sample 2). Estimates of 
log10 NAT-detectable units/mL are indicated on the x-axis. White squares represent quantitative 
assays and grey squares represent qualitative assays. 
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Figure 3. Laboratories mean estimates for Sample 3 (clinical sample). Estimates of log10 NAT-
detectable units/mL are indicated on the x-axis. White squares represent quantitative assays and grey 
squares represent qualitative assays. 
 
 
 
 
 
Figure 4. Laboratories mean estimates for Sample 4 (clinical sample). Estimates of log10 NAT-
detectable units/mL are indicated on the x-axis. White squares represent quantitative assays and grey 
squares represent qualitative assays. 
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Figure 5. Laboratories mean estimates for Sample 5 (clinical sample). Estimates of log10 NAT-
detectable units/mL are indicated on the x-axis. White squares represent quantitative assays and grey 
squares represent qualitative assays. 
 
 
 
 
 
Figure 6. Potency of Sample 2 relative to the candidate WHO standard 11785/16 (Sample 1; 6.39 
log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares represent quantitative 
assays and grey squares represent qualitative assays. 
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Figure 7. Potency of Sample 3 relative to the candidate WHO standard 11785/16 (Sample 1; 6.39 
log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares represent quantitative 
assays and grey squares represent qualitative assays. 
 
 
 
 
 
Figure 8. Potency of Sample 4 relative to the candidate WHO standard 11785/16 (Sample 1; 6.39 
log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares represent quantitative 
assays and grey squares represent qualitative assays. 
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Figure 9. Potency of Sample 5 relative to the candidate WHO standard 11785/16 (Sample 1; 6.39 
log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares represent quantitative 
assays and grey squares represent qualitative assays. 
 
 
 
 
 
Figure 10. CT value-based potency of Sample 2 relative to the candidate WHO standard 11785/16 
(Sample 1; 6.39 log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares 
represent quantitative assays and grey squares represent qualitative assays. 
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Figure 11. CT value-based potency of Sample 3 relative to the candidate WHO standard 11785/16 
(Sample 1; 6.39 log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares 
represent quantitative assays and grey squares represent qualitative assays. 
 
 
 
 
 
Figure 12. CT value-based potency of Sample 4 relative to the candidate WHO standard 11785/16 
(Sample 1; 6.39 log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares 
represent quantitative assays and grey squares represent qualitative assays. 
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Figure 13. CT value-based potency of Sample 5 relative to the candidate WHO standard 11785/16 
(Sample 1; 6.39 log10 IU/mL). Units are expressed as candidate log10 IU/mL. White squares 
represent quantitative assays and grey squares represent qualitative assays. 
 
 
 
 
 
Figure 14. Results from stability testing of the candidate WHO standard 11785/16 (Sample 1).  
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Figure 15. Relationship of mean CT values between the candidate IS (Sample 1, S1) and Sample 2 
(S2), Sample 3 (S3), Sample 4 (S4) and Sample 5 (S5) (based on data of 1:10 dilution). 
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Appendix 2. Instructions for Use for 11785/16. .
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Appendix 3. Study protocol, results and methods reporting forms. 
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